[Hiring] Accounts Receivable Analyst @Sarah Cannon Research Institute

Role Description

Our Accounts Receivable Specialist is responsible for the reconciliation of client receivables in accordance with contractual agreements. This includes review of all Clinical Trial revenues and expenses, as well as interaction with various departments to determine the validity of charges and payments received from sponsors. This is a remote position based in the US; relocation assistance and visa sponsorship are not available.

• Reconcile in detail clinical trial receivables to ensure final billing to pharmaceutical companies is accurate and timely.
• Reconcile Sarah Cannon financial study data across multiple sources.
• Review and interpret contracts and budgets.
• Work with operations and other departments to resolve variances.
• Respond to requests for information from Corporate, Internal Audit, Operations, and Management.
• Perform analysis of contracted revenue triggers to determine eligibility for reimbursement.
• Ensure that all processing and reporting deadlines are consistently achieved.
• Other duties as assigned.

Qualifications

• Bachelor's Degree required.
• 1-2 years' work experience in Accounting or Finance in a medical, clinical trial research, or healthcare-related environment.
• Experience with Microsoft products including above average use of Excel and financial accounting systems such as Quickbooks.
• Knowledge of research techniques to analyze and evaluate financial data and information.

Benefits

• Comprehensive benefits to support physical, mental, and financial well-being.
• Competitive compensation package determined by performance, experience, skills, equity, regular job market evaluations, and geographical markets.
• Additional compensation opportunities such as an annual bonus or long-term incentive opportunities may be offered.

Company Description

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country.

• Conducted more than 850 first-in-human clinical trials since its inception.
• Contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade.
• Research network brings together more than 1,300 physicians enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S.